08:39 AM EDT, 05/29/2024 (MT Newswires) -- PMV Pharmaceuticals ( PMVP ) and Foundation Medicine said Wednesday they are collaborating to develop Foundation Medicine's FoundationOneCDx tissue-based genomic profiling test as a companion diagnostic for PMV's rezatapopt investigational therapy.

Rezatapopt is being evaluated as a potential treatment for locally advanced or metastatic solid tumors with a TP53 Y220C mutation while FoundationOneCDx is expected to identify patients with the TP53 Y220C mutation who may qualify to receive rezatapopt, according to the companies.

Foundation Medicine's genomic profiling tests approved by the US Food and Drug Administration provide both blood- and tissue-based testing options for tracking genomic alterations to guide personalized treatment decisions, the companies said.

Financial terms of the partnership weren't disclosed.

Price: 2.0400, Change: +0.03, Percent Change: +1.49